1.Reproducibility Evaluation
1) Lunate-Capitate Overlap: BCT-view achieved superior reproducibility (SD = 0.10) compared to Gaynor-Hart (SD = 0.46) and Marshall (SD = 0.20).
2) Scaphoid-Trapezium Isolation: BCT-view demonstrated significant improvement (SD = 0.16) versus Gaynor-Hart (SD = 0.60) and Marshall (SD = 0.53).
3) Carpal Tunnel Size: BCT-view showed the lowest variation (SD = 0.15) compared to Gaynor-Hart (SD = 0.60) and Marshall (SD = 0.60).
2. Radiation Dose Evaluation
1) Eye Dose: BCT-view reduced radiation exposure to the eye by 63% compared to Gaynor-Hart (20.96 μSv) and by 30% compared to Marshall (11.02 μSv).
2) Thyroid Dose: BCT-view showed a 55% reduction in thyroid exposure compared to Gaynor-Hart (20.26 μSv) but recorded a 24% increase compared to Marshall (7.35 μSv).
3) Breast Dose: BCT-view reduced breast exposure by 60% compared to Gaynor-Hart (22.94 μSv) and by 5% compared to Marshall (9.67 μSv).
4) Total Dose Comparison: BCT-view demonstrated an overall 60% reduction in total radiation dose compared to Gaynor-Hart and a 7% reduction compared to Marshall.
3. Patient Positioning Evaluation
1) Convenience Scores: BCT-view scored 4.8/5 compared to 3.2/5 (Gaynor-Hart) and 3.4/5 (Marshall).
2) Stability Scores: BCT-view achieved 4.6/5 compared to 2.8/5 (Gaynor-Hart) and 3.7/5 (Marshall).